Advanced medicines regulatory board (AMRB)

The Advanced Medicines Regulatory Board is the dedicated body responsible for the oversight of regenerative therapy and medical product administration within the dynamic charter city's special economic zone. Here is what stakeholders can expect when engaging with the AMRB:

All entities aiming to administer or distribute regenerative therapies and medical products must secure registration with the AMRB, ensuring adherence to the highest standards of patient safety and product efficacy.

The AMRB provides comprehensive guidances, policies, and procedures that outline the approval criteria for new therapies and products, guiding companies through a streamlined regulatory pathway.

In partnership with Institutional Review Boards (IRBs) and Contract Research Organizations (CROs), the AMRB defines rigorous clinical data requirements to uphold the integrity of clinical trials and ensure the reliability of outcomes.

We establish clear guidelines for robust clinical trial conduct and meticulous post-market reporting, fostering transparency and ongoing quality assurance.

Our dedicated team meticulously reviews and approves products and services for patient care, ensuring that only therapies meeting our stringent criteria are authorized for use.

AMRB has established processes and systems to address consumer complaints, conduct corporate audits, and make public announcements, maintaining an environment of trust and accountability.

We work in close coordination with local government and authorities to align our regulations with Prospera's unique regulatory framework, ensuring that our policies not only meet global standards but also serve the local community's needs effectively.

The AMRB is committed to fostering a regulatory environment that prioritizes patient safety, encourages innovation, and supports the growth of the regenerative medicine sector within our vibrant economic landscape.